Here, we demonstrated that the percentage of CD86+ switched memory B cells was higher after anti-CD180 treatment in dcSSc than in HC, suggesting that B cell activation via CD180 could have a role in the pathological antibody production in SSc. The gene discussed is CD180; the disease is systemic sclerosis.